Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alabama for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alabama only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alabama (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Robert Conry (NPI 1548203235)

Field	Value
Entity Type	Individual
Organization	Robert Conry
Address	901 Leighton Ave Ste 602
City	Anniston
State	AL
ZIP	36207
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 13, 2006

Payer Source	Total Paid
Medicare	$2.1M
Medicaid	$0

Key Findings

This provider’s billing is effectively single‑payer: total Medicare revenue is $2.1M and there is no Medicaid billing on file, so Medicare represents the entire recorded public payer footprint for this NPI. The NPI was enumerated 2006-06-13 (~20 years ago), indicating long-standing participation in Medicare.

Revenue is highly concentrated in a handful of specialty drug codes: the precomputed top‑3 codes account for 79.9% of this provider’s Medicare revenue, led by J9271 ($868.6K, 42.7%), J9144 ($560.9K, 27.6%), and J0897 ($194.4K, 9.6%). This concentration means most Medicare dollars flow from a small set of high-cost biologic and supportive‑care injections.

The code mix and dollar distribution are consistent with a hematology/oncology infusion practice: high revenue from J9271 (pembrolizumab), J9144 (daratumumab) and J0897 (denosumab) alongside chemotherapy administration codes such as 96413 and infusion codes 96365 and 96401, which indicate in‑office delivery of IV and injectable cancer therapies. Supportive services appear embedded in the practice, as shown by iron infusion J1437 and ESA J0881 activity.

Competitive standing for top drugs is mixed: J9144 ranks #93 of 615 nationally (85th percentile; typical, unremarkable volume) suggesting a relatively strong national presence for daratumumab administration, while J9271 ranks #383 of 1841 (79th percentile; typical, unremarkable volume) and J0897 ranks #1006 of 10057 (90th percentile; typical, unremarkable volume), indicating the provider is a respectable but not dominant national participant for these agents. These rank/percentile labels point to meaningful, programmatic use of these biologics without signaling market dominance.

Evaluation-and-management and ancillary procedural codes show above‑typical intensity in several areas: 99214 is at the 95th percentile (ranks #23474 of 479517; notably above typical national volume), 96372 is at the 97th percentile (ranks #1588 of 58224; notably above typical national volume), and 36415 is at the 99th percentile (ranks #1004 of 86467; typical, unremarkable volume label notwithstanding the high percentile). Together these suggest a high throughput of clinical visits, injections, and phlebotomy consistent with an active outpatient infusion/oncology clinic.

Laboratory and diagnostic testing are a meaningful ancillary revenue stream: 80053 ($17.9K, 0.9%) and 85025 ($15.9K, 0.8%) appear in the top 25 and both rank in the high national percentiles (80053 at the 97th percentile, 85025 at the 97th percentile), and 88185 (flow cytometry add‑on) contributes $15.1K. This pattern supports the presence of on‑site or closely integrated lab services used for monitoring oncology patients.

From an operational and financial risk perspective, the practice’s dependence on a few high‑revenue biologic codes (top 3 = 79.9%) means revenue is sensitive to utilization changes or formulary/reimbursement shifts affecting those agents. Payers and contracting teams should note that modest shifts in access to J9271 or J9144 could have outsized impacts on billed Medicare dollars for this provider.

The long tenure in Medicare (NPI enumerated 2006-06-13, ~20 years) combined with high percentiles on visit, infusion, and lab codes suggests an established local infusion practice with sustained Medicare volume rather than a newly entered or sporadic billing pattern. That longevity plus concentrated biologic administration points to a stable, procedure‑centric oncology operation focused on office‑based delivery of specialty drugs.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

65 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	20,200	$40	$868.6K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	14,760	$40	$560.9K
J0897	Injection, denosumab, 1 mg	10,800	$20	$194.4K
J1437	Injection, ferric derisomaltose, 10 mg	5,900	$20	$100.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	740	$90	$67.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	460	$90	$42.3K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	12,620	$1	$25.2K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	70	$340	$22.9K
80053	The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel.	1,790	$10	$17.9K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	250	$60	$16K

Showing 1–10 of 65

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 65 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alabama Distribution

Robert Conry — 4 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alabama

Full comparison — all codes billed, vs. state median

65 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	16	30	19,900	$40	$827.2K
J9144	2	10	11,880	$40	$443.8K
J0897	29	200	3,120	$20	$97.7K
J1437	5	40	3,000	$20	$59.1K
J1454	17	20	90	$340	$33.7K
J0881	11	30	7,720	$1	$24.1K
96413	25	150	150	$90	$20.2K
99214	386	7,330	120	$80	$16.8K
82306	206	340	60	$30	$16K
88185	5	30	490	$20	$15.4K

Showing 1–10 of 65

Related Providers

Other providers that share a Tax Identification Number (TIN) with Robert Conry, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
John Waples	AL	Medical Oncology Physician	$9.6M	$0
Marshall Schreeder	AL	Medical Oncology Physician	$3.5M	$0
Heather Brody	AL	Hematology & Oncology Physician	$3.1M	$0
Jorge Diaz	AL	Hematology & Oncology Physician	$2.6M	$0
Naveen Lobo	AL	Medical Oncology Physician	$2.4M	$0
Ali Hachem	AL	Hematology & Oncology Physician	$2.3M	$0
Daniel Schreeder	AL	Hematology & Oncology Physician	$2.3M	$0
Lakshmikanth Katragadda	AL	Hematology & Oncology Physician	$2.1M	$0
Oncology Specialties, P.C.	AL	Hematology & Oncology Physician	$0	$2M
Surrinder Dang	AL	Hematology & Oncology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Robert Conry, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Pediatrics Plus, P.C.	AL	Pediatric Nurse Practitioner	$0	$14.3M
Pulmonary Care Services Inc	AL	Durable Medical Equipment & Medical Supplies	$0	$8M
Anniston Pediatrics, Inc	AL	Pediatrics Physician	$0	$5.7M
The Health Care Authority Of The City Of Anniston	AL	General Acute Care Hospital	$0	$5.6M
Grow Pediatric Therapy LLC	AL	Speech-Language Pathologist	$0	$2.3M
Angela M. Martin, M.d. F.a.a.p.	AL	Pediatrics Physician	$0	$2.1M
North Alabama Women's Center	AL	Specialist	$0	$1.9M
Vishala Chindalore	AL	Rheumatology Physician	$1.7M	$0
Regional Health Management Corporation	AL	Psychiatry Physician	$0	$1.6M
New Beacon Healthcare Group, LLC	AL	Community Based Hospice Care Agency	$0	$1.5M

Robert Conry — Billing Profile & Reimbursement Data

Sign up for Robert Conry — Billing Profile & Reimbursement Data policy alerts

Robert Conry — Billing Profile & Reimbursement Data

Sign up for Robert Conry — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References